EU Ecosystem For Monitoring Of Post-Licensure Vaccine Benefit And Risk: From ADVANCE To VAC4EU Brussels
06.03.19 - 06.03.19
The ADVANCE public-private consortium was launched by the Innovative Medicines Initiative (IMI) in 2013 to bring together all major stakeholder groups interested in the post-marketing monitoring of the health benefits and risks of vaccines. The consortium has demonstrated that the wealth of existing real-world health care data in the EU can be used to generate actionable evidence on vaccine coverage, benefits, and risks.
The event will address the importance of public private collaboration, heterogeneity of data sources, ability to use real world evidence in decision making in the context of the post-marketing vaccine benefit/risk monitoring.
Goal of the conference
1. Demonstrate how ADVANCE has created solutions and a trusted environment to generate evidence on post-licensure coverage, benefits and risk of vaccinations from existing real-world data across different countries
2. Debate whether and how this may help in maintaining confidence in vaccination programs, which is currently at stake with large impact on return of vaccine preventable disease throughout Europe;
3. Demonstrate tools and best practices.
4. Present and discuss the VAC4EU association.
The event will address the importance of public private collaboration, heterogeneity of data sources, ability to use real world evidence in decision making in the context of the post-marketing vaccine benefit/risk monitoring.
Goal of the conference
1. Demonstrate how ADVANCE has created solutions and a trusted environment to generate evidence on post-licensure coverage, benefits and risk of vaccinations from existing real-world data across different countries
2. Debate whether and how this may help in maintaining confidence in vaccination programs, which is currently at stake with large impact on return of vaccine preventable disease throughout Europe;
3. Demonstrate tools and best practices.
4. Present and discuss the VAC4EU association.